Evidence map›Paper›PMID 41540241›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Repeatability of semi-quantitative [

Rutger B Henrar, Matthijs C F Cysouw, Xavier Palard-Novello, Lothar A Schwarte, Pieter G H M Raijmakers, Lioe-Fee de Geus-Oei, Alexander L Vahrmeijer, Geert Kazemier, Albert D Windhorst, Ronald Boellaard and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rutger B HenrarAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Matthijs C F CysouwAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Xavier Palard-NovelloAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Lothar A SchwarteAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Pieter G H M RaijmakersAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Lioe-Fee de Geus-OeiLeiden University Medical Center, Albinusdreef 2, Leiden, the Netherlands.
Alexander L VahrmeijerLeiden University Medical Center, Albinusdreef 2, Leiden, the Netherlands.
Geert KazemierAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Albert D WindhorstAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Ronald BoellaardAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Maqsood YaqubAmsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Daniela E Oprea-Lager *Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Rutger-Jan Swijnenburg *Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands. r.j.swijnenburg@amsterdamumc.nl.ORCID 0000-0002-3980-4634

Funding

Cancer Center Amsterdam 2021-2-29KWF Kankerbestrijding 11289
6 · The paper itself

Abstract

purposeRadiolabelled fibroblast activation protein inhibitors (FAPI) are promising molecular imaging tracers for the diagnosis and staging of pancreatobiliary cancer. To enable treatment response assessment with [

methodsPatients with pathologically confirmed pancreatobiliary cancer (pancreatic ductal adenocarcinoma (PDAC) or cholangiocarcinoma (CCA)) were included. Patients underwent two [

resultsTwelve patients were included (seven PDAC, three perihilar CCA and two intrahepatic CCA). The median injected dose was 216 MBq (interquartile range (IQR) 167-266 MBq) and the median uptake time was 60 min (range 60-68). In total, 70 FAPI-positive lesions were delineated. The RCs of SUV

conclusionSemi-quantitative measurements of [

Indexed as

Biliary Tract NeoplasmsPancreatic NeoplasmsPositron Emission Tomography Computed TomographyAgedAged, 80 and overFemaleFibroblast Activation Protein AlphaGallium RadioisotopesHumansMaleMiddle AgedQuinolinesReproducibility of ResultsFAPI-46Fibroblast Activation Protein AlphaGallium RadioisotopesQuinolines[68Ga]Ga-FAPI-46LAFOV PET/CTPancreatobiliary cancerRepeatabilityTest-retest

Identifiers

PMID41540241
PMCPMC13121203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.